On May 18, 2017 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic diseases, reported that updated clinical data from the fully enrolled, ongoing Phase 2 study (DRIVE PK) of AG-348 in adults with pyruvate kinase (PK) deficiency, a rare, potentially debilitating, congenital anemia, will be presented at the 22nd Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) taking place June 22-25, 2017 in Madrid, Spain. AG-348 is a wholly owned, novel, first-in-class, oral activator of both wild-type (normal) and mutated pyruvate kinase-R (PKR) enzymes (Press release, Agios Pharmaceuticals, MAY 18, 2017, View Source [SID1234519209]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstracts are listed below and available online on the EHA (Free EHA Whitepaper) conference website: View Source!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531

Oral presentation by Agios:

Title: Effects of AG-348, a pyruvate kinase activator, in patients with Pyruvate Kinase Deficiency: updated results from the DRIVE-PK study
Date & Time: Saturday, June 24, 2017 from 11:30-11:45 a.m. CET
Session Title: Sickle cell disease, enzymes
Abstract Code: S451
Location: Room N109
Presenter: Rachael Grace, M.D., Dana-Farber Boston Children’s Cancer and Blood Disorder Center
Updated data from the DRIVE PK study will be presented at the time of the meeting.

Poster presentation by Agios collaborator:

Title: Ex-vivo treatment of red blood cells from 15 Pyruvate Kinase (PK)-deficient patients with AG-348, an allosteric activator of PK-R, increases enzymatic activity, protein stability and ATP levels
Date & Time: Saturday, June 24, 2017 from 5:30-7:00 p.m. CET
Session Title: Enzymes and sickle cell disease
Abstract Code: P614
Location: Poster area (Hall 7)
Author: Richard van Wijk, Ph.D., University Medical Center Utrecht

Encore presentations by Agios and Celgene:

Title: Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study
Date & Time: Saturday, June 24, 2017 from 4:00-4:15 p.m. CET
Oral Abstract Session: Targeted treatment of AML
Abstract Code: S471
Location: Hall D
Presenter: Eytan Stein, M.D., Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College

Title: Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2)
Poster Session Date & Time: Friday, June 23, 2017 from 5:15-6:45 p.m. CET
Session Title: Acute myeloid leukemia – Clinical 3
Abstract Code: P215
Location: Poster area (Hall 7)
Author: Amir Tahmasb Fathi, M.D., Massachusetts General Hospital and Harvard Medical School

About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company’s website at www.agios.com.

About Agios/Celgene Collaboration
IDHIFA (enasidenib) and AG-881 are part of Agios’ global strategic collaboration with Celgene Corporation focused on cancer metabolism. Under the terms of the 2010 collaboration agreement, Celgene has worldwide development and commercialization rights for IDHIFA (enasidenib). Agios continues to conduct clinical development activities within the IDHIFA (enasidenib) development program and is eligible to receive reimbursement for those development activities and up to $95 million in remaining payments assuming achievement of certain milestones and royalties on net sales. Celgene and Agios intend to co-commercialize IDHIFA (enasidenib) in the U.S. Celgene will reimburse Agios for costs incurred for its co-commercialization efforts.